Thomas B Brunner1, Cynthia L Eccles. 1. Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom. thomas.brunner@rob.ox.ac.uk
Abstract
PURPOSE: this report aims to provide an overview on radiotherapy and chemotherapy in extrahepatic biliary duct carcinoma (BDC). PATIENTS AND METHODS: a PubMed research identified clinical trials in BDC through April 1, 2010 including randomised controlled trials, SEER analyses and retrospective trials. Additionally, publications on the technical progress of radiotherapy in or close to the liver were analysed. RESULTS: most patients with cholangiocarcinoma present with unresectable disease (80-90%), and more than half of the resected patients relapse within 1 year. Adjuvant and palliative treatment options need to be chosen carefully since 50% of the patients are older than 70 years at diagnosis. Adjuvant radiotherapy or chemotherapy after complete resection (R0) has not convincingly shown a prolongation of survival but radiotherapy did after R1 resection. However, data suggest that liver transplantation could offer long-term survival in selected patients when combined with neoadjuvant chemoradiotherapy in patients with marginally resectable disease. For patients with unresectable biliary tract carcinoma (BTC), palliative stenting was previously the treatment of choice. But recent SEER analyses show that radiotherapy prolongs survival, relieves symptoms and contributes to biliary decompression and should be regarded as the new standard. Novel technical advances in radiotherapy may allow for dose-escalation and could significantly improve outcome for patients with cholangiocarcinoma. CONCLUSION: both the literature and recent technical progress corroborate the role of radiotherapy in BDC offering chances for novel clinical trials. Progress is less pronounced in chemotherapy.
PURPOSE: this report aims to provide an overview on radiotherapy and chemotherapy in extrahepatic biliary duct carcinoma (BDC). PATIENTS AND METHODS: a PubMed research identified clinical trials in BDC through April 1, 2010 including randomised controlled trials, SEER analyses and retrospective trials. Additionally, publications on the technical progress of radiotherapy in or close to the liver were analysed. RESULTS: most patients with cholangiocarcinoma present with unresectable disease (80-90%), and more than half of the resected patients relapse within 1 year. Adjuvant and palliative treatment options need to be chosen carefully since 50% of the patients are older than 70 years at diagnosis. Adjuvant radiotherapy or chemotherapy after complete resection (R0) has not convincingly shown a prolongation of survival but radiotherapy did after R1 resection. However, data suggest that liver transplantation could offer long-term survival in selected patients when combined with neoadjuvant chemoradiotherapy in patients with marginally resectable disease. For patients with unresectable biliary tract carcinoma (BTC), palliative stenting was previously the treatment of choice. But recent SEER analyses show that radiotherapy prolongs survival, relieves symptoms and contributes to biliary decompression and should be regarded as the new standard. Novel technical advances in radiotherapy may allow for dose-escalation and could significantly improve outcome for patients with cholangiocarcinoma. CONCLUSION: both the literature and recent technical progress corroborate the role of radiotherapy in BDC offering chances for novel clinical trials. Progress is less pronounced in chemotherapy.
Authors: L A Dawson; C J McGinn; D Normolle; R K Ten Haken; S Walker; W Ensminger; T S Lawrence Journal: J Clin Oncol Date: 2000-06 Impact factor: 44.544
Authors: Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater Journal: N Engl J Med Date: 2010-04-08 Impact factor: 91.245
Authors: Julie K Heimbach; Gregory J Gores; Michael G Haddock; Steven R Alberts; Scott L Nyberg; Michael B Ishitani; Charles B Rosen Journal: Semin Liver Dis Date: 2004-05 Impact factor: 6.115
Authors: Christopher H Crane; Kenneth O Macdonald; J N Vauthey; Patt Yehuda; Thomas Brown; Steven Curley; Adrian Wong; Marc Delclos; Chusilp Charnsangavej; Nora A Janjan Journal: Int J Radiat Oncol Biol Phys Date: 2002-07-15 Impact factor: 7.038
Authors: H A Pitt; A Nakeeb; R A Abrams; J Coleman; S Piantadosi; C J Yeo; K D Lillemore; J L Cameron Journal: Ann Surg Date: 1995-06 Impact factor: 12.969
Authors: K Kim; E K Chie; J-Y Jang; S W Kim; S-W Han; D-Y Oh; S-A Im; T-Y Kim; Y-J Bang; S W Ha Journal: Strahlenther Onkol Date: 2012-03-10 Impact factor: 3.621
Authors: Florian Sterzing; Thomas B Brunner; Iris Ernst; Wolfgang W Baus; Burkhard Greve; Klaus Herfarth; Matthias Guckenberger Journal: Strahlenther Onkol Date: 2014-08-05 Impact factor: 3.621
Authors: D Habermehl; K Lindel; S Rieken; K Haase; B Goeppert; M W Büchler; P Schirmacher; T Welzel; J Debus; S E Combs Journal: Strahlenther Onkol Date: 2012-04-13 Impact factor: 3.621